Article
Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
22 Mar 2018
Abstract excerpt
BACKGROUND: Phosphatase and tensin homolog (PTEN) is one of the most frequently inactivated tumor suppressors in breast cancer. While PTEN itself is not considered a druggable target, PTEN synthetic-sick or synthetic-lethal (PTEN-SSL) genes are potential drug targets in PTEN-deficient breast cancers. Therefore, with the aim of identifying potential targets for precision breast cancer therapy, we sought to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
